Central role of cell cycle regulation in the antitumoral action of ocoxin
[EN]Nutritional supplements which include natural antitumoral compounds could represent safe and efficient additives for cancer patients. One such nutritional supplement, Ocoxin Oral solution (OOS), is a composite formulation that contains several antioxidants and exhibits antitumoral properties in...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universidad de Salamanca (USAL) |
| Repositorio: | GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| OAI Identifier: | oai:dnet:gredos______::27b69dc6030b4ad9df78e77c3578e9e1 |
| Acceso en línea: | http://hdl.handle.net/10366/171371 |
| Access Level: | acceso embargado |
| Palabra clave: | Acute myeloid leukemia Antioxidants Apoptosis Cell cycle p27 Small-cell lung cancer Zinc Sulfate Ascorbic Acid Cell Cycle Plant Extracts Gene Expression Regulation Humans Vitamin B 6 Cell Line Neoplasms Transcriptome Folic Acid Pantothenic Acid Vitamin B 12 Animals Mice 24 Ciencias de la Vida 2302.21 Biología Molecular neoplasias ácido pantoténico humanos ratones línea celular vitamina B 6 extractos de plantas ácido fólico regulación de la expresión génica animales ácido ascórbico ciclo celular transcriptoma vitamina B 12 sulfato de zinc |
| Sumario: | [EN]Nutritional supplements which include natural antitumoral compounds could represent safe and efficient additives for cancer patients. One such nutritional supplement, Ocoxin Oral solution (OOS), is a composite formulation that contains several antioxidants and exhibits antitumoral properties in several in vitro and in vivo tumor conditions. Here, we performed a functional genomic analysis to uncover the mechanism of the antitumoral action of OOS. Using in vivo models of acute myelogenous leukemia (AML, HEL cells, representative of a liquid tumor) and small-cell lung cancer (GLC-8, representative of a solid tumor), we showed that OOS treatment altered the transcriptome of xenografted tumors created by subcutaneously implanting these cells. Functional transcriptomic studies pointed to a cell cycle deregulation after OOS treatment. The main pathway responsible for this deregulation was the E2F-TFDP route, which was affected at different points. The alterations ultimately led to a decrease in pathway activation. Moreover, when OOS-deregulated genes in the AML context were analyzed in patient samples, a clear correlation with their levels and prognosis was observed. Together, these data led us to suggest that the antitumoral effect of OOS is due to blockade of cell cycle progression mainly caused by the action of OOS on the E2F-TFDP pathway. |
|---|